Affinity Chromatography slowing you down?

GORE Protein Capture Devices in 1.0 mL, 3.5 mL, 9 mL, 58 mL, 116 mL, 232 mL, 250 mL, 500 mL and 1L sizes.

Learn more

Traditional affinity chromatography technology has not kept pace with increased titers and other upstream process improvements, leading to bottlenecks and lower productivity in downstream protein A purification. To shorten processing times, traditional resin-based protein A is often over-sized or underutilized – simply to keep up.*

*Reference: “Disrupting Downstream Process Bottlenecks.” Genetic Engineering, June 14, 2018.








Increase productivity: GORE Protein Capture Devices with Protein A utilize a unique membrane solution that provides a binding capacity advantage at high flow rates and improves the speed of purification versus traditional protein A resin technologies. Compare our Dynamic Binding Capacity (DBC) to that of agarose bead-based columns:


Graph of binding capacity of GORE Device (PROA103) vs standard technology

Representative dynamic binding capacity demonstrated with a 9 mL GORE Device (PROA103) versus a standard agarose bead-based technology, using a purified monoclonal antibody.

GORE Protein Capture Devices are approximately 6–10x faster than traditional (agarose bead-based) chromatography methods, which operate at typical residence times of 3–5 minutes (180–300 seconds).

Render of microsopic monocolonal antibody in blue and green

Designed for affinity purification in early drug discovery screening, late stage optimization, process development, clinical and routine bioprocessing for

  • monoclonal antibodies (mAbs)
  • next-generation molecules that utilize the Fc region for Protein A binding

The columns are compatible with standard chromatography systems.


Part Number Description Applications 
PROA101 1.0 mL Device Drug discovery
PROA102 3.5 mL Device Drug discovery
PROA103  9.0 mL Device     Drug discovery, late stage optimization, process development, early GMP applications
PROA201  58 mL Device Process development, clinical (GMP) applications  
PROA202  116 mL Device Clinical (GMP) applications  
PROA203  232 mL Device Clinical and Routine Manufacturing (GMP) applications
PROA301 250 mL Device Clinical and Routine Manufacturing (GMP) applications
PROA302 500 mL Device Clinical and Routine Manufacturing (GMP) applications
PROA303 1 L Device Clinical and Routine Manufacturing (GMP) applications



GORE Protein Capture Devices with immobilized Protein A* can improve throughput and yields in downstream purification by reducing overall process time through a combination of increased binding capacity and fast flow rates. These pre-packed columns use a unique membrane that offers high dynamic binding capacity at short residence time. Designed to increase the efficiency of protein A column purification processes, the Devices accommodate rapid cycle capability at low pressure drop, along with demonstrated ability to withstand multiple cleaning cycles. This increased productivity offers researchers the potential for a faster path to clinical trials.

  GORE Protein Capture Devices with Protein A (all sizes)
Dynamic binding capacity ≥ 30 mg/mL ≥ 40 mg/mL
Residence time 20 seconds 30 seconds
Number of cleaning cycles 0.2 N NaOH for 3 minutes up to 100 cycles 0.2 N NaOH for 3 minutes up to 100 cycles

*recombinant Protein A


The GORE Protein Capture Device scales across sizes without compromising binding capacity or speed to quickly and effectively capture antibodies as shown in this overlay of a 1 mL, 9 mL and 58 mL bind-elute curve and dynamic binding capacity graph.

Overlaid chromatogram showing 1.0 mL, 9.0 mL, and 58.0 mL device UV absorbance

Overlaid chromatogram showing 1 mL (blue), 9 mL (red) and 58 mL (green) UV absorbance. The difference in UV of harvest reflects different LC instruments.

Overlaid DBC10% comparison of 58 mL (red) and 250 mL (blue).

Overlaid DBC10% comparison of 58 mL (red) and 250 mL (blue).

Want complete technical and product performance information, including detailed test parameters, additional yield data, purity profiles and operating conditions?



The GORE Protein Capture Devices with Protein A can streamline antibody purification processes because they incorporate a proprietary membrane composite.

Unlike traditional support matrices, the composite membrane bed maintains a linear relationship between pressure drop and a wide range of flow rates. Because this unique structure remains stable, the membrane bed is not vulnerable to collapse, channeling or alteration of the bed.

Performance under pressure
Pressure Drop for a 58 mL Device (PROA201)
Graph showing pressure drop vs. flow rate for GORE Device

Example pressure drop vs. flow rate relationship for a GORE Device when using phosphate buffer at room temperature. For reference, 116 mL/min equates to 30 seconds residence time.

Pressure drop consistency
Example of pressure drop vs. residence time consistency for the 58 mL (blue), 250 mL (red), and 500 mL (grey) when using phosphate buffer at room temperature.

Example of pressure drop vs. residence time consistency for the 58 mL (blue), 250 mL (red), and 500 mL (grey) when using phosphate buffer at room temperature. 


Materials of construction
Device housing components Polypropylene Polypropylene and Polyether ether ketone (PEEK) primarily*
Frit material(s) Polypropylene Polyether ether ketone (PEEK)
Polyvinylidene fluoride (PVDF)
Membrane support matrix Proprietary composite
Ligand Recombinant Protein A
Connectors 10-32 threaded fittings (PROA101/PROA102)

10-32 coned thread port (PROA103)
5/16-24 Flat-bottom fittings (PROA201)

1/2-20 flat-bottom threaded fittings (PROA301)
3/4" Tri clamp
(0.984" (OD))

* For details:


For Validation





GORE Protein Capture Devices are compatible with standard pre-packed column chromatography systems, and are available in sizes as listed in table below. Contact Gore for pricing and availability. These Devices for protein A purification are not available in all regions.

Part Number Description
PROA101 1.0 mL Device
PROA102 3.5 mL Device
PROA103 9.0 mL Device
PROA201 58 mL Device
PROA202 116 mL Device
PROA203 232 mL Device
PROA301 250 mL Device
PROA302 500 mL Device
PROA303 1 L Device

See Validation Guides for performance specifications and evaluations.

Regulatory Compliance and Quality

GORE Protein Capture Devices are manufactured following the applicable material quality and regulatory requirements, including relevant Good Manufacturing Processes as defined in the Gore PharmBIO quality system which is certified to ISO 13485 and ISO 15378. For current applicable compliance statements and quality control information:



Recent News

Press Release


Posted April 11, 2023

W. L. Gore & Associates, Inc. (“Gore”), a global materials science company, continues to build on its growing portfolio of protein capture devices with the introduction of its 250mL, 500mL and 1L GORE® Protein Capture Devices with Protein A. The offerings follow commer-cial availability of its 116mL and 232mL sizes introduced in mid 2022.


Join W. L. Gore & Associates for the Live + Virtual Bioprocessing Summit Europe

March 14, 2023 - March 16, 2023

Join W. L. Gore & Associates at BioProcessing Summit Europe, Europe’s Premier Conference to Optimize Your Bioprocesses


Visit GORE at BioProcess International in San Diego

February 27, 2023 - March 2, 2023

Join W. L. Gore & Associates for BioProcess International, the largest BioProcessing event for learning how to accelerate promising biologics, cell & gene therapies towards commercial success.

Press Release

AGC Biologics and Gore Collaborate on New Protein A-based Purification Technology and Contract Manufacturing Services for Antibody Therapies

Posted December 12, 2022

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a collaboration with W.L. Gore & Associates (Gore) that features Protein A affinity purification technology from Gore alongside the global CDMO’s contract development and manufacturing services. By using GORE and AGC Biologics, biopharmaceutical companies can improve downstream purification processes, eliminate column bioburden issues, increase product material yields in the research and development (R&D) stages, and help lower costs for clinical manufacturing.

View all News & Events

NOT INTENDED FOR USE in medical device or food contact applications or with radiation sterilization.